Figure 4.

miR-124a overexpression does not inhibit subcutaneous tumor formation nor established tumor growth. (A) Schematic representation of in vivo tumor growth model: The 113/6-4L -GFP-Luciferase cells were stably transduced with doxycycline-inducible control TRIPZ-miR-Scr or TRIPZ-miR-124a tagged with a tRFP reporter and injected with Matrigel (1:1) into the flank of NSG female mice. Cells were treated with doxycycline (2 µg/ml) prior to injection, and mice were fed doxycycline chow since the intracardiac inoculation. (B) Constitutive miR-124a overexpression in 113/6-4L cells did not affect tumor volume (C) nor weight at termination of the experiment (Day 34). (D) Schematic representation of in vivo growth after implantation: The 113/6-4L -GFP-Luciferase cells were stably transduced with doxycycline-inducible control TRIPZ-miR-Scr or TRIPZ-miR-124a tagged with a tRFP reporter and injected with Matrigel (1:1) into the flank of NOG/SCID female mice. Once tumors were palpable (Day 14 post-injection), mice were fed doxycycline chow (200 mg/kg). (E) Inducible miR-124a overexpression in established tumors did not affect tumor volume (F) nor weight at termination of the experiment (Day 34). ns, non significant.